Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

NCT02849080 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

504

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: sitagliptin

Sponsor

Novo Nordisk A/S